ESC 365 - The future of SGLT2 inhibition in heart failure: managing patients without T2DM?

HFA Premium Access

The future of SGLT2 inhibition in heart failure: managing patients without T2DM?

Session: Heart Failure, diabetes & SGLT2 inhibition: time to change practice?

Topic: Pharmacotherapy

Speaker: Professor A. Voors (Groningen, NL)

Organised by PACE-CME, Physicians' Academy for Cardiovascular Education, supported with an educational grant from Boehringer Ingelheim

Event: Heart Failure 2019

Congress Presentation

Add to my library

About the speaker

Professor Adriaan Voors

University Medical Centre Groningen, Groningen (Netherlands (The))

77 presentations

1 follower

4 more presentations in this session

The essentials for diabetes and heart failure.

Speaker: Professor M. Cowie (Cambridge, GB)

Why could patients with heart failure and T2DM benefit from SGLT2 inhibition?

Speaker: Professor S. Verma (Toronto, CA)

Real world practices and outcomes in the management of heart failure patients with T2DM.

Speaker: Professor C. Lam (Singapore, SG)

Panel discussion - Heart Failure, diabetes & SGLT2 inhibition: time to change practice?

Speaker: Professor M. Cowie (Cambridge, GB)

Access the full session

Heart Failure, diabetes & SGLT2 inhibition: time to change practice?

Speakers: Professor A. Voors, Professor M. Cowie, Professor S. Verma, Professor C. Lam, Professor M. Cowie

About the event

Heart Failure 2019

25 May - 28 May 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources